 RedHill Biopharma Ltd NASDAQ:RDHL has reported its financial results and operational highlights for the third quarter ended September 30, 2021, showing a second consecutive quarter of record net revenues, increased gross profit and growth in Talicia and Movantik prescriptions. The company also announced it is accelerating its two advanced coronavirus COVID-19 pill clinical programs, both of which act independently of spike protein mutations via unique host-targeted mechanisms of action, and that hold potential versus Omicron and other SARS-CoV-2 variants. 